Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
After bringing in $150m in its initial public offering on 15 October, Aligos Therapeutics, Inc. now has taken on a deep-pocketed partner as Merck & Co., Inc. is investing in its oligonucleotide platform to discover and develop novel candidates for non-alcoholic steatohepatitis and an additional target in the cardiometabolic/fibrotic health space
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?